Don't miss our weekly PhD newsletter | Sign up now Don't miss our weekly PhD newsletter | Sign up now

We have 16 Pharmacology (systems biology) PhD Projects, Programmes & Scholarships

Discipline

Discipline

Medicine

Location

Location

All locations

Institution

Institution

All Institutions

PhD Type

PhD Type

All PhD Types

Funding

Funding

All Funding


Pharmacology (systems biology) PhD Projects, Programmes & Scholarships

We have 16 Pharmacology (systems biology) PhD Projects, Programmes & Scholarships

10+ fully funded PhD positions at the IMPRS for Molecular Organ Biology

10+ fully funded PhD positions at the IMPRS for Molecular Organ Biology. PhD Studies in the Heart of Europe. The International Max Planck Research School for Molecular Organ Biology (IMPRS-MOB) offers fully funded positions to talented and enthusiastic students holding a relevant Master‘s degree. Read more

Targeting the MAPK scaffold protein KSR1 for the treatment of prostate cancer

  Research Group: Institute of Cancer Therapeutics
Prostate cancer is one of the leading causes of male cancer deaths. It arises when individual cells escape their normal growth control mechanisms and proliferate in an uncontrolled fashion. Read more

MSc by Research: Glueing proteins together with small molecules

Recent advances from the Ciulli Lab and others have contributed to the establishment of a game-changing new modality of chemical intervention into biological system – one that moves beyond the state-of-the-art. Read more

Novel strategy for treatment of chronic wounds via multi-functional liposomal nanocarriers

  Research Group: Medicines Development and Pharmaceutical Sciences
A confounding issue of non-healing skin wounds is the presence of pathogenic bacteria, that protect themselves from conventional antibiotic treatments by encasing themselves within protective shields (biofilms). Read more

ERK5 MAPK signalling in Alzheimer’s disease

  Research Group: Pharmacology and Experimental Therapeutics
Neurodegenerative diseases have devastating effects on individuals’ lives and our society, with no effective treatments available. Read more

Molecular characterisation of a novel transporter for the atypical antipsychotic clozapine

Schizophrenia is a severe psychiatric illness affecting about 24 million people worldwide. Schizophrenia can have a devastating effect on a patient’s life and is associated with increased mortality, with life expectancy reduced on average by 15 years compared to that of the general population. Read more

Molecular Mechanisms of Receptor and Ion Channel Regulation in Pain and Inflammation

Are you ready to delve into the captivating world of molecular signaling and unravel the mysteries of the cardiovascular and nervous systems? We are thrilled to offer an exhilarating PhD opportunity at the forefront of scientific exploration. Read more

New Drugs for Brain Tumours: Prodrugs of Diazopropyne

  Research Group: Medicines Development and Pharmaceutical Sciences
The propargyl group, introduced to temozolomide-like drugs for brain tumours by our colleagues in Nottingham, shows considerable pre-clinical promise and… Read more

Our Mission: to Educate, Nurture and Discover for the benefit of Human Health

Founded in 1784 as the professional body for surgical training in Ireland, RCSI has evolved in the years since to become one of the world's leading health sciences universities. Read more

(MRC DTP CASE) Understanding how tumour associated macrophages control the tumour immune landscape in NF2-Schwannomatosis

Type 2 Neurofibromatosis (NF2), now referred to as NF2-Schwannomatosis (or NF2-SWN), is a rare autosomal dominant tumour pre-disposition syndrome characterised by growth of typically benign tumours throughout the nervous system. Read more

Personalising cancer treatment with tumour evolution modelling using AI-based genomics biomarkers and PK/PD

Tumour heterogeneity is a major problem limiting the efficacy of targeted oncological therapies. Most advanced tumours eventually become resistant to the treatments, ultimately making the patient succumb to metastatic disease. Read more

Network-based predictive modelling of cardiovascular disease risk

The risk of cardiovascular disease (CVD) is orchestrated by multiple factors. QRISK models (currently QRISK3) have been used in the UK to estimate CVD risk within the next 10 years for individuals without CVD. Read more

Filtering Results